2024 HIV Treatment and Prevention Agents Specialty Pharmacies 
Pharmacy Times
JULY 16, 2025
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. 2 Vepdegestrant is an oral PROTAC that targets ER and is the first agent of its type to be evaluated in a phase 3 trial.
Pharmacy Times
JULY 24, 2025
Pharmacists are positioned to personalize HFpEF care through monitoring, patient-centered strategies, and shared decision-making, enhancing treatment adherence and outcomes. 1 In a recent Pharmacy Times Clinical Forum, pharmacists gathered to discuss how they are navigating this treatment landscape and evaluating the emergence of finerenone.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 18, 2025
Safe disposal options include DEA Take Back Days, pharmacy kiosks, law enforcement kiosks, mail-back envelopes, and home disposal methods. Image credit: OM | stock.adobe.com Why Proper Disposal Matters Disposing of medications appropriately helps prevent environmental contamination of water and soil.
Pharmacy Times
AUGUST 8, 2025
SHOW MORE Intranasal insulin shows promise in targeting memory regions of the brain, offering new hope for Alzheimer disease treatment in older adults. Insulin absorption varies between cognitively normal individuals and those with mild cognitive impairment, with higher uptake in the former.
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A. 2,3 Hypertension remains a major public health challenge both in the United States and globally.
Pharmacy Times
AUGUST 7, 2025
Pharmacists are essential in managing OIC, advising on treatment, monitoring effectiveness, and identifying contraindications and potential complications. Pharmacological support often starts with OTC agents, like water-holding laxatives (e.g., polyethylene glycol and lactulose) and stimulant laxatives (e.g., bisacodyl and senna).
Pharmacy Times
JUNE 16, 2025
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.
Expert insights. Personalized for you.
Let's personalize your content